Clarifying the Plausible Mechanism Pathway

Abstract

Get full access to this article

View all access options for this article.

References

Prasad

, Makary

. FDA’s new plausible mechanism pathway. N Engl J Med, 2025; 393(23):2365–2367; doi: 10.1056/NEJMsb2512695

Musunuru

, Grandinette

, Wang

, et al. Patient-Specific in vivo gene editing to treat a rare genetic disease. N Engl J Med, 2025; 392(22):2235–2243; doi: 10.1056/NEJMoa2504747

Barrett

, Cannon

, Mingozzi

, et al. Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases. Mol Ther, 2025; 33(11):5316–5326; doi: 10.1016/j.ymthe.2025.09.049

Federal Food, Drug, and Cosmetic Act 21 U.S.C. § 356k. https://www.law.cornell.edu/uscode/text/21/356k. 2025.

Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/platform-technology-designation-program-drug-development 2025.

Kiem

H-P

, Baum

, Bushman

, et al. Charting a clear path: The ASGCT standardized pathways conference. Mol Ther, 2014; 22(7):1235–1238; doi: 10.1038/mt.2014.95

Nyberg

, Carter

, Chen

, et al. Workshop on long-term follow-up of participants in human gene transfer research. Mol Ther, 2004; 10(6):976–980; doi: 10.1016/j.ymthe.2004.10.011